ProDigest
ActiveSummary
ProDigest has been active since 2008 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €5.2m and a net result of €32,740. Equity is growing by about 8.7% per year across the filed financial years. Its solvency ranks better than 65% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Financials · financial year 2025, abbreviated format
Equity
€5.2m▲ 0.6%
2024 · €5.1m
Total assets
€7.8m▲ 1.0%
2024 · €7.8m
Net result
€32,740▼ 70.5%
2024 · €110,989
Working capital
€4.4m▲ 14.4%
2024 · €3.9m
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result falls in 2025; 2025 is 99% below 2024.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result€0.001m
2025
Net result€0.03m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€7.8m
2025
Equity€5.2m
2025
Debt€2.7m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€4.4m
2025
How much of each euro of turnover is left from operations (EBIT margin) and what the assets earn (return on assets).
Return on assets (ROA)0.4%
2025
The share of the company financed with its own means. The higher it is, the better it absorbs a shock.
Solvency65.9%
2025
Short-term assets per euro of short-term debt. Above 1 the short-term debts are covered.
Current ratio3.07
2025
Average staff in full-time equivalents (FTE).
Staff (FTE)39.8
2025
Use the arrow keys on the chart for the figures per year.
Sector: the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€0.03m--€0.4m€2.4m€2.8m▲ 15.6%€0.06m▼ 98.0%-€0.9m€0.09m€0.001m▼ 98.6%
Net result€0.009m--€0.4m€2.2mabove the sector's middle half€2.2mabove the sector's middle half▼ 1.2%€0.01mwithin the sector's middle half▼ 99.5%-€0.8mbelow the sector's middle half€0.1mwithin the sector's middle half€0.03mwithin the sector's middle half▼ 70.5%
Equity€2.1m-€1.5m▼ 28.2%€3.7mabove the sector's middle half▲ 145%€5.9mabove the sector's middle half▲ 58.5%€5.9mabove the sector's middle half▲ 0.2%€5.0mabove the sector's middle half▼ 14.4%€5.1mabove the sector's middle half▲ 2.2%€5.2mabove the sector's middle half▲ 0.6%
Total assets€4.8m-€4.5m▼ 7.8%€6.5mabove the sector's middle half▲ 45.2%€8.6mabove the sector's middle half▲ 32.2%€8.4mabove the sector's middle half▼ 2.1%€8.7mabove the sector's middle half▲ 4.2%€7.8mabove the sector's middle half▼ 11.2%€7.8mabove the sector's middle half▲ 1.0%
Debt€2.7m-€3.0m▲ 7.8%€2.8m▼ 5.8%€2.7m▼ 2.6%€2.5m▼ 6.9%€3.7m▲ 47.2%€2.6m▼ 29.3%€2.7m▲ 1.6%
Working capital€1.8m-€1.8m▼ 5.3%€3.9mabove the sector's middle half▲ 125%€5.9mabove the sector's middle half▲ 50.2%€5.3mabove the sector's middle half▼ 10.7%€4.2mabove the sector's middle half▼ 21.4%€3.9mabove the sector's middle half▼ 6.6%€4.4mabove the sector's middle half▲ 14.4%
Solvency43.3%-33.7%▼ 9.6pp57.0%within the sector's middle half▲ 23.3pp68.3%within the sector's middle half▲ 11.3pp69.9%within the sector's middle half▲ 1.6pp57.5%within the sector's middle half▼ 12.4pp66.1%within the sector's middle half▲ 8.7pp65.9%within the sector's middle half▼ 0.2pp
Current ratio1.82-1.79▼ 0.032.95within the sector's middle half▲ 1.164.03within the sector's middle half▲ 1.083.72within the sector's middle half▼ 0.312.46within the sector's middle half▼ 1.262.66within the sector's middle half▲ 0.193.07within the sector's middle half▲ 0.41
Return on assets (ROA)0.2%--9.3%▼ 9.5pp33.8%above the sector's middle half▲ 43.0pp25.2%above the sector's middle half▼ 8.5pp0.1%within the sector's middle half▼ 25.1pp-9.6%within the sector's middle half▼ 9.8pp1.4%within the sector's middle half▲ 11.1pp0.4%within the sector's middle half▼ 1.0pp
Staff (FTE)33.9-36.9above the sector's middle half38.6above the sector's middle half▲ 4.6%43.3above the sector's middle half▲ 12.2%45.8above the sector's middle half▲ 5.8%40.5above the sector's middle half▼ 11.6%39.8above the sector's middle half▼ 1.7%
above
within
below
the middle half of NACE 72, Scientific research and development: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated format does not require them.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €7.8m
Fixed assets
€1.2m ▼ 18.7%
Current assets
€6.6m ▲ 5.8%
Equity and liabilities €7.8m
Equity
€5.2m ▲ 0.6%
Debt
€2.7m ▲ 1.6%
Debt's share of the balance-sheet total rises from 33.9% to 34.1%. Equity and debt are higher.
Key figures and ratios
EBITDA
€570,521▼
2024 · €638,844
Cash flow
€601,924▼
2024 · €656,431
Quick ratio
2.88▲
2024 · 2.47
Debt to equity
0.52▲
2024 · 0.51
ROE
0.6%▼
2024 · 2.2%
Interest coverage
15.39▲
2024 · 8.88
Debt ≤ 1 year
€2.1m▼
2024 · €2.3m
Debt > 1 year
€0▼
2024 · €141,209
Staff costs
€3.6m▲
2024 · €3.6m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 6,049 companies that looked in July 2024 the way this one looks now, 0.4% went bankrupt within 24 months and 95.9% are still going.
- Small
- 10 to 20 years old
- solvency 30% or more
- a profit under 5% of the balance sheet
0.4%
went bankrupt
3.6%
stopped otherwise
95.9%
still going
For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,472 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 6,049 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €0.006m | €0.02m | €0.01m | €0 | €40 | - |
| Remuneration, social security and pensions62 | - | €3.0m | - | €2.8m | €3.3m | €3.9m | €3.6m | €3.6m | ▲ 1.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €0.3m | €0.3m | €0.2m | €0.2m | €0.3m | €0.5m | €0.5m | €0.6m | ▲ 4.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4 | - | - | - | - | - | - | €0.01m | €0.01m | ▼ 21.0% |
| Other operating charges640/8 | - | €0.04m | - | €0.006m | €0.01m | €0.007m | €0.01m | €0.009m | ▼ 14.7% |
| Non-recurring operating charges66A | - | €0.03m | - | €0.02m | €0.01m | €0 | - | - | - |
| Gross operating margin9900 | €3.0m | €2.9m | €5.1m | €5.9m | €3.7m | €3.5m | €4.2m | €4.2m | ▼ 0.4% |
| Operating profit (loss)9901 | €0.03m | -€0.4m | €2.4m | €2.8m | €0.06m | -€0.9m | €0.09m | €0.001m | ▼ 98.6% |
| Financial income75/76B | - | €0.006m | - | €0.05m | €0.03m | €0.1m | €0.1m | €0.1m | ▼ 20.2% |
| Recurring financial income75 | €0.006m | €0.006m | €0.03m | €0.05m | €0.03m | €0.1m | €0.1m | €0.1m | ▼ 20.2% |
| Financial charges65/66B | - | €0.04m | - | €0.02m | €0.07m | €0.09m | €0.1m | €0.07m | ▼ 35.8% |
| Recurring financial charges65 | €0.02m | €0.04m | €0.05m | €0.02m | €0.04m | €0.09m | €0.07m | €0.04m | ▼ 48.5% |
| Non-recurring financial charges66B | - | - | - | €0.006m | €0.03m | €409 | €0.04m | €0.03m | ▼ 12.6% |
| Profit (loss) for the period before taxes9903 | €0.01m | -€0.4m | €2.4m | €2.8m | €0.01m | -€0.8m | €0.1m | €0.03m | ▼ 70.5% |
| Income taxes67/77 | €0.004m | €0 | €0.2m | €0.7m | €0.003m | €0.001m | €0 | - | - |
| Profit (loss) for the period9904 | €0.009m | -€0.4m | €2.2m | €2.2m | €0.01m | -€0.8m | €0.1m | €0.03m | ▼ 70.5% |
| Transfer from tax-exempt reserves789 | - | €0 | - | - | - | - | - | - | - |
| Transfer to tax-exempt reserves689 | - | - | - | €0 | - | - | - | - | - |
| Profit (loss) for the period to be appropriated9905 | €0.2m | - | €2.1m | €2.2m | €0.01m | -€0.8m | €0.1m | €0.03m | ▼ 70.5% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €4.8m | €4.5m | €6.5m | €8.6m | €8.4m | €8.7m | €7.8m | €7.8m | ▲ 1.0% |
| Fixed assets21/28 | €0.7m | €0.5m | €0.5m | €0.7m | €1.2m | €1.7m | €1.5m | €1.2m | ▼ 18.7% |
| Intangible fixed assets21 | €0.002m | €0.001m | €0.001m | €0 | - | €0.02m | €0.02m | €0.06m | ▲ 146% |
| Tangible fixed assets22/27 | €0.7m | €0.5m | €0.5m | €0.7m | €1.2m | €1.7m | €1.5m | €1.1m | ▼ 22.1% |
| Plant, machinery and equipment23 | - | €0.4m | - | €0.6m | €1.1m | €1.6m | €1.4m | €1.0m | ▼ 25.6% |
| Furniture and vehicles24 | - | €0.03m | - | €0.09m | €0.1m | €0.08m | €0.06m | €0.1m | ▲ 55.2% |
| Other tangible fixed assets26 | - | €0.01m | - | €0.01m | €0 | - | - | - | - |
| Assets under construction and advance payments27 | - | - | - | - | - | €0.02m | €0 | - | - |
| Financial fixed assets28 | €0.004m | €0.001m | €0.001m | €0.001m | €0.001m | €0.001m | €0.05m | €0.05m | ▼ 1.9% |
| Current assets29/58 | €4.1m | €4.0m | €6.0m | €7.9m | €7.2m | €7.0m | €6.2m | €6.6m | ▲ 5.8% |
| Amounts receivable after more than one year29 | - | €0.2m | - | €0.1m | €0.1m | €1.5m | €1.6m | €1.9m | ▲ 19.5% |
| Trade receivables290 | - | - | - | - | - | - | €0.08m | €0.08m | = |
| Other amounts receivable291 | - | €0.2m | - | €0.1m | €0.1m | €1.5m | €1.5m | €1.8m | ▲ 20.4% |
| Stocks and contracts in progress3 | €0.1m | €0.3m | €0.2m | €0.4m | €0.3m | €0.5m | €0.4m | €0.4m | ▼ 11.3% |
| Stocks30/36 | - | €0.3m | - | €0.4m | €0.3m | €0.4m | €0.4m | €0.4m | ▼ 11.3% |
| Contracts in progress37 | - | - | - | - | - | €0.1m | €0 | - | - |
| Amounts receivable within one year40/41 | €2.9m | €2.7m | €3.8m | €4.0m | €4.4m | €4.2m | €3.4m | €3.4m | ▼ 0.6% |
| Trade receivables40 | - | €2.2m | - | €3.4m | €3.5m | €3.5m | €3.0m | €2.9m | ▼ 3.8% |
| Other amounts receivable41 | - | €0.5m | - | €0.6m | €0.9m | €0.6m | €0.4m | €0.5m | ▲ 21.9% |
| Current investments50/53 | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | €0.1m | €0 | ▼ 100% |
| Cash at bank and in hand54/58 | €1.0m | €0.7m | €1.8m | €3.2m | €2.2m | €0.4m | €0.5m | €0.7m | ▲ 43.4% |
| Deferred charges and accrued income490/1 | - | €0.05m | - | €0.01m | €0.1m | €0.2m | €0.2m | €0.3m | ▲ 17.7% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €4.8m | €4.5m | €6.5m | €8.6m | €8.4m | €8.7m | €7.8m | €7.8m | ▲ 1.0% |
| Equity10/15 | €2.1m | €1.5m | €3.7m | €5.9m | €5.9m | €5.0m | €5.1m | €5.2m | ▲ 0.6% |
| Contributions10/11 | €0.3m | €0.2m | - | €0.2m | €0.2m | €0.2m | €0.2m | €0.2m | = |
| Capital10 | - | €0.2m | - | - | - | - | - | - | - |
| Issued capital100 | - | €0.2m | - | - | - | - | - | - | - |
| Reserves13 | €1.2m | €1.0m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Legal reserve130 | - | €0.02m | - | - | - | - | - | - | - |
| Tax-exempt reserves132 | - | €0.07m | - | - | - | - | - | - | - |
| Distributable reserves133 | - | €0.9m | - | €1.1m | €1.1m | €1.1m | €1.1m | €1.1m | = |
| Profit (loss) carried forward14 | €0.6m | €0.3m | €2.4m | €4.5m | €4.6m | €3.7m | €3.8m | €3.9m | ▲ 0.9% |
| Amounts payable17/49 | €2.7m | €3.0m | €2.8m | €2.7m | €2.5m | €3.7m | €2.6m | €2.7m | ▲ 1.6% |
| Amounts payable after more than one year17 | €0.2m | €0.1m | €0.2m | €0.3m | €0.08m | €0.5m | €0.1m | €0 | ▼ 100% |
| Financial debts170/4 | - | €0.1m | - | €0.3m | €0.08m | €0.5m | €0.1m | €0 | ▼ 100% |
| Amounts payable within one year42/48 | €2.3m | €2.2m | €2.0m | €2.0m | €1.9m | €2.8m | €2.3m | €2.1m | ▼ 8.4% |
| Current portion of amounts payable after more than one year42 | - | €0.2m | - | €0.2m | €0.5m | €0.6m | €0.6m | €0.1m | ▼ 75.2% |
| Financial debts43 | - | €0.2m | - | - | - | - | €71 | €0.005m | ▲ 7,233% |
| Credit institutions430/8 | - | €0.2m | - | - | - | - | €71 | €0.005m | ▲ 7,233% |
| Trade debts44 | €1.4m | €0.8m | €0.8m | €0.7m | €0.7m | €0.7m | €0.7m | €0.6m | ▼ 14.8% |
| Suppliers440/4 | - | €0.8m | - | €0.7m | €0.7m | €0.7m | €0.7m | €0.6m | ▼ 14.8% |
| Advances received on contracts in progress46 | - | €0.4m | - | €0.4m | €0.3m | €0.7m | €0.6m | €1.0m | ▲ 76.7% |
| Taxes, remuneration and social security45 | - | €0.3m | - | €0.7m | €0.4m | €0.4m | €0.5m | €0.5m | ▼ 6.1% |
| Taxes450/3 | - | €0.03m | - | €0.3m | €0.06m | €0.003m | €0.02m | €0.004m | ▼ 80.4% |
| Remuneration and social security454/9 | - | €0.3m | - | €0.3m | €0.4m | €0.4m | €0.5m | €0.5m | ▼ 3.0% |
| Other amounts payable47/48 | - | €0.2m | - | €0.02m | €0.02m | €0.4m | €0.07m | €0 | ▼ 100% |
| Accrued charges and deferred income492/3 | - | €0.6m | - | €0.4m | €0.5m | €0.4m | €0.1m | €0.5m | ▲ 269% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €0.009m | -€0.4m | €2.2m | €2.2m | €0.01m | -€0.8m | €0.1m | €0.03m | ▼ 70.5% |
| + Depreciation and write-downs630 | €0.3m | €0.3m | €0.2m | €0.2m | €0.3m | €0.5m | €0.5m | €0.6m | ▲ 4.4% |
| Operating cash flow (approximation) | €0.3m | -€0.1m | €2.4m | €2.4m | €0.4m | -€0.4m | €0.7m | €0.6m | ▼ 8.3% |
| Investment in fixed assets (approximation) | - | -€0.02m | -€0.2m | -€0.4m | -€0.8m | -€1.1m | -€0.3m | -€0.3m | ▲ 16.1% |
| Change in cash | - | -€0.3m | €1.1m | €1.5m | -€1.0m | -€1.8m | €0.04m | €0.2m | ▲ 361% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 17 filings with the National Bank
| Financial year | Type | Filed | Reference |
|---|---|---|---|
| 31-12-2025 | abbreviated format | 02-07-2026 | 2026-00242358 |
| 31-12-2024 | abbreviated format | 08-10-2025 | 2025-00539276 |
| 31-12-2023 | abbreviated format | 25-06-2024 | 2024-00198189 |
| 31-12-2022 | abbreviated format | 27-06-2023 | 2023-00174985 |
| 31-12-2021 | abbreviated format | 28-06-2022 | 2022-20140236 |
| 31-12-2020 | abbreviated format | 25-06-2021 | 2021-25400560 |
| 31-12-2019 | abbreviated format | 24-09-2020 | 2020-55500336 |
| 31-12-2018 | abbreviated format | 06-06-2019 | 2019-16600342 |
| 31-12-2017 | abbreviated format | 28-06-2018 | 2018-25900218 |
| 31-12-2016 | abbreviated format | 22-06-2017 | 2017-20200367 |
Similar companies · same sector, comparable size
ATB THERAPEUTICS
BE 0677.980.015
Marche-en-Famenne · equity €5,081,751
Orgenesis (Belgium)
BE 0540.866.555
Marche-en-Famenne · equity €5,079,736
NANOMEGAS
BE 0862.188.755
Elsene · equity €5,034,542
ORIONIS BIOSCIENCES
BE 0635.962.088
Gent · equity €4,924,048
BOTALYS
BE 0834.134.177
Ath · equity €4,903,461
Of the 757 active companies whose main activity is research and development on biotechnology (NACE 72101), figures are known for 485. 197 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector
Subsidies and aid
Flemish government
2022 to 2025 · 18 entries · €1.3m awarded · €718,869 paid| Year | Entries | Awarded | Paid |
|---|---|---|---|
| 2025 | 7 | €519,160 | €184,264 |
| 2024 | 5 | €2,300 | €273,331 |
| 2023 | 4 | €399,116 | €127,664 |
| 2022 | 2 | €334,003 | €133,610 |
European research
7 projects · 1 as coordinator · €2.7m EU contributionProgrammes
Projects
Use of Microorganisms for Carotenoids Delivery: Next Generation of Probiotics for Cardiovascular Disease
Satiety Innovation
New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting Janus kinases
Dietary Fibers supporting Gut and Immune Function - From polysaccharide compound to health claim
Deciphering the fungus-host-microbiota interplay to improve the management of fungal infections
Show 2 more projects
Beneficial effects of dietary bioactive peptides and polyphenols on cardiovascular health in humans
Biopolymer Based FOOd Delivery Systems
Public contracts
4 awards · 2024 to 2025
Dostawa symulatora układu pokarmowego człowieka
Beschaffung eines komplexen Systems zur Simulierung von Verdauungs- und Fermentationsprozessen im Magen-Darmtrakt von Mensch und Tier
Intestinal Modelling System: Qualification
Intestinal Modelling System: Requirements
Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.